Hoe verhoudt 3320's PE Ratio zich tot zijn concurrenten?

3320 is een goede waarde op basis van zijn Price-To-Earnings Ratio (8.4x) vergeleken met het gemiddelde van gelijken (12.5x).

Hoe verhoudt 3320's PE Ratio zich tot andere bedrijven in de HK Pharmaceuticals industrie?

3320 is duur op basis van de Price-To-Earnings -ratio ( 8.4 x) vergeleken met het Hong Kong Pharmaceuticals -industriegemiddelde ( 8.4 x).

Wat is 3320's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

3320 is een goede waarde op basis van de Price-To-Earnings -ratio ( 8.4 x) vergeleken met de geschatte eerlijke Price-To-Earnings -ratio ( 12.1 x).

Wat is de reële prijs van 3320 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

3320 ( HK$5.43 ) wordt verhandeld onder onze schatting van [[eerlijke waarde]] ( HK$20.54 )

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

De koersdoelstelling ligt meer dan 20 % hoger dan de huidige aandelenkoers, maar analisten zijn het statistisch gezien niet eens over de overeengekomen marge.

China Resources Pharmaceutical Group (SEHK:3320) - Aandelenkoers, Nieuws & Analyse

3320 Overzicht aandelen

China Resources Pharmaceutical Group Limited, een investeringsholding, houdt zich bezig met onderzoek en ontwikkeling, productie, distributie en verkoop van farmaceutische en andere gezondheidsproducten op het Chinese vasteland en daarbuiten. Meer informatie

3320 fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	2/6
Prestaties in het verleden	5/6
Financiële gezondheid	5/6
Dividenden	3/6

Beloningen

Verhandeld tegen 73.6% onder onze schatting van de reële waarde

De winst zal naar verwachting met 7.62% per jaar groeien

De winst groeide het afgelopen jaar met 11.7%

Risicoanalyse

Heeft een hoog schuldenniveau

China Resources Pharmaceutical Group Limited Concurrenten

CSPC Pharmaceutical Group

SEHK:1093

HK$60.3b

Grand Pharmaceutical Group

SEHK:512

HK$16.2b

United Laboratories International Holdings

SEHK:3933

HK$18.1b

Sino Biopharmaceutical

SEHK:1177

HK$59.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor China Resources Pharmaceutical Group
Historische aandelenkoersen
Huidige aandelenkoers	HK$5.43
52 Week Hoogtepunt	HK$7.11
52 Week Laag	HK$4.45
Bèta	0.42
11 maand verandering	-7.50%
3 maanden verandering	-1.27%
1 Jaar Verandering	6.68%
33 jaar verandering	56.94%
5 jaar verandering	-22.32%
Verandering sinds IPO	-39.73%

Recent nieuws en updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17

Rendement voor aandeelhouders

	3320	HK Pharmaceuticals	HK Markt
7D	-2.2%	-2.1%	0.05%
1Y	6.7%	-9.4%	11.5%

Rendement versus industrie: 3320 overtrof de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement -9.4 % opleverde.

Rendement versus markt: 3320 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 11.5 % opleverde.

Prijsvolatiliteit

Is 3320's price volatile compared to industry and market?
3320 volatility
3320 Average Weekly Movement	6.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Stabiele aandelenkoers: 3320 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van 3320 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	72,764	Xiaosong Bai	www.crpharm.com

China Resources Pharmaceutical Group Limited, een investeringsmaatschappij, houdt zich bezig met onderzoek en ontwikkeling, productie, distributie en verkoop van farmaceutische en andere gezondheidsproducten op het Chinese vasteland en internationaal. Het bedrijf is actief in vier segmenten: Farmaceutische Productie, Farmaceutische Distributie, Farmaceutische Detailhandel en Overige. Het bedrijf biedt een scala aan chemische geneesmiddelen, Chinese geneesmiddelen en v, evenals voedings- en gezondheidsproducten voor verschillende therapeutische gebieden, waaronder cardiovasculaire en cerebrovasculaire, spijsverteringskanaal, metabolisme en endocriene, respiratoire, orthopedische, oncologische, medische voeding, gastro-enterologie, kindergeneeskunde, urogenitaal systeem, hoest en verkoudheid, anti-infectie, dermatologie, infuusoplossingen, enz.

China Resources Pharmaceutical Group Limited Samenvatting

Hoe verhouden de winst en inkomsten van China Resources Pharmaceutical Group zich tot de beurswaarde?
3320 fundamentele statistieken
Marktkapitalisatie	HK$34.05b
Inkomsten(TTM)	HK$4.06b
Inkomsten(TTM)	HK$269.22b

8.4x

Koers/Winstverhouding

0.1x

P/S-verhouding

Is 3320 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
3320 resultatenrekening (TTM)
Inkomsten	CN¥250.48b
Kosten van inkomsten	CN¥210.97b
Brutowinst	CN¥39.51b
Overige uitgaven	CN¥35.73b
Inkomsten	CN¥3.78b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.60
Brutomarge	15.77%
Nettowinstmarge	1.51%
Schuld/Eigen Vermogen Verhouding	77.1%

Hoe presteerde 3320 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.3%

Huidig dividendrendement

39%

Uitbetalingsratio

3320 Overzicht aandelen

Beloningen

Risicoanalyse

China Resources Pharmaceutical Group Limited Concurrenten

SEHK:1093

HK$60.3b

SEHK:512

HK$16.2b

SEHK:3933

HK$18.1b

SEHK:1177

HK$59.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 18%

Upcoming dividend of HK$0.091 per share

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

New minor risk - Financial position

Recent updates

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 18%

Upcoming dividend of HK$0.091 per share

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

New minor risk - Financial position

First half 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.45 in 1H 2023)

China Resources Pharmaceutical Group Limited Announces Resignation of Bai Xiaosong as Chief Executive Officer

China Resources Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 29, 2024

China Resources Pharmaceutical Group Limited Announces Directorate Changes

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.17 per share

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

Investor sentiment improves as stock rises 17%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Full year 2023 earnings: EPS and revenues miss analyst expectations

Now 20% overvalued

China Resources Pharmaceutical Group Limited Announces Change of Company Secretary

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Dong-E-E-Jiao Company Limited Provides Earnings Guidance for the Three Months Ended 31 March 2024

Now 21% overvalued

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Dividend of HK$0.17 announced

China Resources Pharmaceutical Group Limited, Annual General Meeting, May 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024

China Resources Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

China Resources Pharmaceutical Group Limited Announces Management Changes, Effective on 27 December 2023

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: HK$0.48 (vs HK$0.48 in 1H 2022)

China Resources Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 31, 2023

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

New minor risk - Dividend sustainability

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

China Resources Pharmaceutical Group Limited Announces Executive Changes

China Resources Pharmaceutical Group Limited Approves to Declare A Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.16 per share at 2.1% yield

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

Price target increased by 7.6% to HK$7.97

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Price target increased by 8.9% to HK$7.60

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued

Now 22% undervalued

China Resources Pharmaceutical Group Limited Announces Appointment of Non-Executive Director

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Less than half of directors are independent

Investor sentiment improved over the past week

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group Limited Announces Retirement of Mr. Tan Ying as Non-Executive Director

First half 2022 earnings released: EPS: HK$0.48 (vs HK$0.39 in 1H 2021)

China Resources Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 25, 2022

China Resources Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022